Company news

ImmuneOnco IMM01 clinical trial successfully completed the first patient's first administration

2019-9-19 0:00:00Click:267

On September 19, 2019, ImmuneOnco announced that IMM01, the first Fc fusion protein drug targeting human CD47 in China, was successfully administered for the first time in the Hematological Hospital of the Chinese Academy of Medical Sciences. At present, the testee is in normal condition.

"This is another important progress of IMM01 project following the approval of the National Drug Administration (NMPA) clinical trial, and it has become another important milestone in the development of ImmuneOnco's many anti-tumor immunotherapy products." Dr. Tian Wenzhi, founder of ImmuneOnco, is confident and expecting the clinical trial of IMM01. "With the successful administration of the first trial, ImmuneOnco has officially become a biopharma company entering the stage of clinical research. With its unique research and development advantages in the field of anti-cancer immunity and abundant product lines of cancer drugs, ImmuneOnco brings more safe, effective and affordable new drugs to cancer patients.”

About IMM01

IMM01 is a new generation of immune checkpoint inhibitors with independent intellectual property rights based on the technology platform of "mAb-Trap" of ImmuneOnco. Aiming at CD47, the target of immune regulation, IMM01 activates the phagocytic effect of macrophages on tumor cells and presents the phagocytosis-treated tumor antigens to T cells, so as to play a strong role and large tumor immunotherapy effect. ImmuneOnco perfectly solved the core pain point of CD47 target drug research and development.

 About ImmuneOnco

 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Shanghai Zhangjiang High-tech Park. The company is mainly committed to the development of immunotherapy products for cancer, including bispecific antibodies, new recombinant proteins, and CAR-NK cell therapy. The common feature of our products is to stimulate the immune system of patients to play an anti-tumor effect, and ultimately inhibit the growth of cancer cells, reversing the resulting series of malignant symptoms, so that patients gradually return to a healthy body state.


Contact us

Address: Room 502, 1043 Harley Road, Pudong New Area, Shanghai, China

Tel: +86 21 5835 6573

Website: www.immuneonco.com